Barclays’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-99,618
| Closed | -$909K | – | 5698 |
|
|
2025
Q2 | $909K | Buy |
99,618
+40,031
| +67% | +$294K | ﹤0.01% | 3402 |
|
|
2025
Q1 | $474K | Sell |
59,587
-35,861
| -38% | -$263K | ﹤0.01% | 3562 |
|
|
2024
Q4 | $518K | Sell |
95,448
-32,341
| -25% | -$198K | ﹤0.01% | 3799 |
|
|
2024
Q3 | $923K | Buy |
127,789
+49,171
| +63% | +$450K | ﹤0.01% | 3406 |
|
|
2024
Q2 | $854K | Buy |
78,618
+704
| +0.9% | +$9.02K | ﹤0.01% | 2690 |
|
|
2024
Q1 | $1.46M | Sell |
77,914
-119,146
| -60% | -$2.75M | ﹤0.01% | 2825 |
|
|
2023
Q4 | $4.27M | Sell |
197,060
-9,353
| -5% | -$185K | ﹤0.01% | 2247 |
|
|
2023
Q3 | $4.25M | Buy |
206,413
+62,454
| +43% | +$1.8M | ﹤0.01% | 1417 |
|
|
2023
Q2 | $6.77M | Sell |
143,959
-3,103
| -2% | -$154K | ﹤0.01% | 1174 |
|
|
2023
Q1 | $6.17M | Buy |
147,062
+50,739
| +53% | +$2.18M | ﹤0.01% | 1417 |
|
|
2022
Q4 | $3.67M | Sell |
96,323
-9,243
| -9% | -$353K | ﹤0.01% | 1846 |
|
|
2022
Q3 | $4.13M | Buy |
105,566
+99,159
| +1,548% | +$3.83M | ﹤0.01% | 1280 |
|
|
2022
Q2 | $206K | Sell |
6,407
-30,890
| -83% | -$1.04M | ﹤0.01% | 3404 |
|
|
2022
Q1 | $1.24M | Sell |
37,297
-26,055
| -41% | -$979K | ﹤0.01% | 2237 |
|
|
2021
Q4 | $2.69M | Buy |
63,352
+12,885
| +26% | +$539K | ﹤0.01% | 2182 |
|
|
2021
Q3 | $2.24M | Buy |
50,467
+22,157
| +78% | +$1.02M | ﹤0.01% | 2250 |
|
|
2021
Q2 | $1.61M | Sell |
28,310
-36,222
| -56% | -$2.56M | ﹤0.01% | 2345 |
|
|
2021
Q1 | $4.83M | Buy |
64,532
+60,523
| +1,510% | +$4.96M | ﹤0.01% | 1545 |
|
|
2020
Q4 | $347K | Buy |
4,009
+203
| +5% | +$15K | ﹤0.01% | 3468 |
|
|
2020
Q3 | $233K | Sell |
3,806
-14,050
| -79% | -$712K | ﹤0.01% | 3747 |
|
|
2020
Q2 | $741K | Sell |
17,856
-79,068
| -82% | -$2.87M | ﹤0.01% | 3017 |
|
|
2020
Q1 | $2.78M | Sell |
96,924
-11,495
| -11% | -$666K | ﹤0.01% | 1980 |
|
|
2019
Q4 | $7.83M | Buy |
108,419
+72,410
| +201% | +$8.91M | ﹤0.01% | 1584 |
|
|
2019
Q3 | $5.05M | Buy |
36,009
+17,075
| +90% | +$2.86M | ﹤0.01% | 1844 |
|
|
2019
Q2 | $3.47M | Buy |
18,934
+16,856
| +811% | +$2.88M | ﹤0.01% | 2262 |
|
|
2019
Q1 | $330K | Sell |
2,078
-42,510
| -95% | -$6.16M | ﹤0.01% | 4447 |
|
|
2018
Q4 | $4.27M | Buy |
44,588
+31,973
| +253% | +$3.66M | ﹤0.01% | 1704 |
|
|
2018
Q3 | $1.78M | Sell |
12,615
-48,862
| -79% | -$7.54M | ﹤0.01% | 3012 |
|
|
2018
Q2 | $9.62M | Buy |
61,477
+51,480
| +515% | +$8.08M | 0.01% | 1255 |
|
|
2018
Q1 | $1.61M | Sell |
9,997
-194,333
| -95% | -$33M | ﹤0.01% | 2704 |
|
|
2017
Q4 | $33.7M | Buy |
204,330
+172,037
| +533% | +$16.7M | 0.03% | 560 |
|
|
2017
Q3 | $2.01M | Sell |
32,293
-148,462
| -82% | -$11.7M | ﹤0.01% | 2361 |
|
|
2017
Q2 | $14.4M | Buy |
180,755
+179,524
| +14,584% | +$13M | 0.02% | 765 |
|
|
2017
Q1 | $88K | Sell |
1,231
-66,873
| -98% | -$3.92M | ﹤0.01% | 4973 |
|
|
2016
Q4 | $3.48M | Buy |
68,104
+67,682
| +16,038% | +$3.19M | ﹤0.01% | 1657 |
|
|
2016
Q3 | $19K | Sell |
422
-47,909
| -99% | -$1.95M | ﹤0.01% | 5503 |
|
|
2016
Q2 | $1.46M | Buy |
48,331
+45,937
| +1,919% | +$1.53M | ﹤0.01% | 2282 |
|
|
2016
Q1 | $77K | Buy |
2,394
+1,823
| +319% | +$64.2K | ﹤0.01% | 4527 |
|
|
2015
Q4 | $33K | Sell |
571
-11,717
| -95% | -$580K | ﹤0.01% | 4997 |
|
|
2015
Q3 | $516K | Buy |
12,288
+10,632
| +642% | +$655K | ﹤0.01% | 3324 |
|
|
2015
Q2 | $121K | Buy |
1,656
+1,185
| +252% | +$76.2K | ﹤0.01% | 4538 |
|
|
2015
Q1 | $24K | Sell |
471
-96
| -17% | -$4.13K | ﹤0.01% | 5732 |
|
|
2014
Q4 | $21K | Buy |
+567
| New | +$21.1K | ﹤0.01% | 6303 |
|
Other funds holding SAGE
IA
HNB
Barclays's SAGE Position: Q3 2025 in Review
Barclays sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 99,618 shares — an estimated $909K sold.
Barclays first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $33.7M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Barclays reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Barclays sold 99,618 Sage Therapeutics shares in Q3 2025, an estimated $909K.
- Barclays first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
- Barclays's Sage Therapeutics position peaked at $33.7M in Q4 2017.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.